Twelve years ago, Bain Capital quietly wrote a ₹700 crore cheque for a stake in a Pune drugmaker most people had never heard of.
Today, they walked out the door for the last time.
And the math is delicious.
December 2013.
Bain buys a 13% stake in Emcure Pharma from Blackstone in a secondary deal worth ₹700 crore.
No fanfare. No headlines. Just a patient bet on an unsexy Indian generics company.
Fast forward to today.
Bain just sold its final 1% stake via a clean-out block deal — pocketing ₹350 crore at a floor price of ₹1,817 per share.
Let that sink in.
👉 The last 1% alone fetched half of what they paid for the entire 13%.
The real flex came in July 2024.
Emcure went public at a price band of ₹960–₹1,008 per share.
The IPO drew $11 billion in bids for a $234 million issue. Absurdly oversubscribed.
And the stock?
📈 Up 30%+ in just the last six months.
📈 Up nearly 80% from its issue price.
Bain didn't dump and run.
They trimmed. Patiently. Block deal after block deal. Two more just this FY27.
Until today's final exit. Curtain call.
This isn't just a PE win story.
It's a masterclass in three things:
Kotak and Axis ran today's block. Bain declined to comment.
They don't need to. The tape spoke for them.
While one chapter closes, three more are opening:
The best returns in India aren't being made by the loudest bets.
They're being made by the funds willing to wait a decade in a boring sector and let compounding do its thing.
Bain entered Emcure when nobody cared.
They exited when everybody did.
That's the whole game.
That's all for now!
